Filing Analysis
Synaptogenix, Inc. has implemented aggressive cost-cutting measures, including significant salary reductions for the CEO and CSO, alongside the termination of a Phase 1 clinical trial due to slow enrollment. The company is also forming a special committee to explore strategic opportunities, signaling potential distress or restructuring.
🚩 Red Flags
- Significant reduction in executive compensation (CEO and CSO) typically indicates severe liquidity constraints or cash runway issues.
- Termination of clinical trials for the lead drug candidate (Bryostatin-1) due to enrollment failures, impacting the core value proposition.
- Formation of a 'special committee' often precedes M&A activity, spin-offs, or significant corporate restructuring in distressed micro-caps.
📋 Key Facts
- CEO Dr. Alan J. Tuchman's term extended through Jan 31, 2025, with automatic monthly renewals; base salary reduced to $12,500/month effective Jan 1, 2025.
- CSO Dr. Daniel L. Alkon entering a new consulting agreement effective Jan 1, 2025, with fee reduced to $16,000/month.
- Termination of Phase 1 clinical trial for Bryostatin-1 in multiple sclerosis due to slow enrollment rates.
- Formation of a special committee to explore strategic opportunities to enhance investor value.
Synaptogenix, Inc. held its Annual Meeting of Stockholders on December 6, 2024, reporting results for four proposals including director elections and equity plan amendments.
🚩 Red Flags
- Proposal 2 involves authorization of share issuance that could lead to significant dilution (up to 20% of common stock outstanding) via convertible preferred stock and warrants.
📋 Key Facts
- Quorum was present with 846,988 shares (approx. 54.03% of outstanding common stock) represented in person or by proxy.
- Joshua Silverman and William S. Singer were elected to the Board of Directors until the 2027 annual meeting.
- Stockholders approved a proposal authorizing the Board to issue common stock underlying convertible preferred stock/warrants from a Sept 10, 2024 agreement (up to 20% of outstanding shares).
- The 2020 Equity Incentive Plan was amended to increase authorized shares from 175,000 to 675,000.
- Stockholders ratified Stephano Slack as the independent registered public accounting firm for fiscal year 2024.
Synaptogenix, Inc. announced the resignation of its independent auditor, Morison Cogen LLP, effective September 30, 2024, due to the firm's decision to exit providing audit services to publicly traded companies. The company has appointed Stephano Slack LLC as its new independent registered public accounting firm for the fiscal year ending December 31, 2024.
🚩 Red Flags
- Auditor change: While the reason provided (firm exiting public company audits) is a structural business decision by the auditor rather than a dispute with management, auditor changes in micro-cap companies often trigger increased scrutiny and potential delays in financial reporting.
📋 Key Facts
- Morison Cogen LLP resigned on September 30, 2024.
- Resignation reason: Morison Cogen is exiting from providing audit services to publicly traded companies.
- The company stated there were no disagreements with the outgoing auditor regarding accounting principles or practices for fiscal years 2022, 2023, and interim 2024.
- Stephano Slack LLC was engaged as the new auditor on October 4, 2024.
- The change is effective for the fiscal year ending December 31, 2024.
Synaptogenix, Inc. has completed a $5 million private placement of newly created Series C Convertible Preferred Stock and warrants. The terms include mandatory cash redemptions starting October 31, 2024, and significant dividend escalations in the event of default.
🚩 Red Flags
- Mandatory cash redemptions starting in less than two months (Oct 31, 2024) create immediate liquidity pressure.
- Dividend step-up to 15% upon 'Triggering Events' (e.g., failure to pay or failure to maintain registration statement).
- Restrictive covenants regarding indebtedness, asset transfers, and cash distributions.
- Potential for significant dilution via the Series C conversion feature.
📋 Key Facts
- Completed private placement of Series C Convertible Preferred Stock and warrants for $5 million gross proceeds.
- Initial conversion price set at $4.00 per share.
- Mandatory cash redemption in equal quarterly installments commencing October 31, 2024, at 107% of the installment amount.
- Preferred shares carry a 5% annual dividend, which increases to 15% per annum upon a 'Triggering Event'.
- The company must seek stockholder approval for issuances exceeding 19.99% of outstanding shares by December 31, 2024.
- Redemption rights can be exercised by holders one year after issuance.
Synaptogenix, Inc. entered into a $5.0 million securities offering involving Series C convertible preferred stock and warrants via both a registered direct offering and a private placement. The deal includes highly dilutive terms, including a 'full ratchet' anti-dilution provision on warrants and significant redemption obligations.
🚩 Red Flags
- Highly dilutive structure: Potential for up to 1,250,000 warrant shares plus over 1.2 million conversion shares.
- Full Ratchet Anti-Dilution: Warrants are subject to full ratchet adjustments, which is extremely punitive to existing shareholders in down rounds.
- Redemption Obligations: Mandatory quarterly cash redemptions starting Oct 31, 2024, create significant liquidity pressure.
- Death Spiral Features: The combination of high dividends (up to 15%) and redemption rights upon 'Triggering Events' (like failure to maintain registration) is characteristic of predatory financing.
- Registration Rights Agreement: Includes liquidated damages if the company fails to register shares promptly.
📋 Key Facts
- Aggregate gross proceeds from the Offering are expected to be $5.0 million.
- The offering consists of 1,793 shares of Series C Preferred Stock (Registered) and 3,207 shares of Unregistered Preferred Shares.
- Conversion price for Preferred Stock is set at an initial $4.00 per share.
- Warrants were issued to acquire up to 1,250,000 shares of Common Stock with a five-year term and $4.00 exercise price.
- The Company must redeem Series C Preferred Shares in quarterly installments starting October 31, 2024, at 107% of the installment amount.
- Preferred shares carry a 5% cash dividend, which increases to 15% per annum upon a 'Triggering Event'.
- Warrants include a 'full ratchet' anti-dilution adjustment if common stock is issued below $4.00.
Synaptogenix, Inc. filed an amendment to its Certificate of Designations to extend the maturity date of its Series B Convertible Preferred Stock from August 31, 2024, to September 9, 2024.
🚩 Red Flags
- Extremely short-term maturity extension (9 days) suggests imminent liquidity pressure or a struggle to secure long-term financing.
- The need for rapid, incremental extensions often precedes a default or restructuring event.
📋 Key Facts
- The Company extended the maturity date of Series B Convertible Preferred Stock by only 9 days (from Aug 31 to Sept 9, 2024).
- The extension is subject to further extensions pursuant to the terms of the Certificate of Designations.
- Amendment filed with the Delaware Secretary of State on September 3, 2024.
Synaptogenix, Inc. entered into a third amendment to the employment offer letter for its CEO, Alan J. Tuchman, Ph.D., effective June 7, 2024. The amendment extends his term through December 7, 2024, with provisions for automatic monthly renewals.
🚩 Red Flags
- Short-term extension (only through Dec 2024) may suggest uncertainty regarding long-term leadership stability or upcoming contract renegotiations.
📋 Key Facts
- Effective date of amendment: June 7, 2024
- CEO Alan J. Tuchman's employment term extended to December 7, 2024
- Amendment includes automatic monthly renewal provisions thereafter
- The amendment is the third such modification to his original offer letter dated December 7, 2020
Synaptogenix, Inc. has implemented a one-time reverse stock split of its common stock at a ratio of 1-for-25. The transaction became effective after the close of trading on April 4, 2024.
🚩 Red Flags
- Reverse stock split (often used to combat delisting or improve share price perception).
- Ticker symbol change often accompanies significant restructuring or distress.
📋 Key Facts
- Reverse stock split ratio: 1-for-25.
- Effective Date/Time: April 4, 2024, at 5:00 p.m. ET (after market close).
- New Ticker Symbol: SNPX (previously TAOX).
- Fractional shares will be paid out in cash based on the closing price of April 4, 2024.
- Proportionate adjustments applied to stock options, warrants, and convertible securities.